Skip to main content
Erschienen in: International Journal of Hematology 2/2021

24.04.2021 | Original Article

Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis

verfasst von: Mohammad Rafiee, Mehdi Allahbakhshian Farsani, Vahid Amiri, Abbas Hajifathali, Ahmad Gharehbaghian, Mohammad Hossein Mohammadi

Erschienen in: International Journal of Hematology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

The involvement of microRNAs in the regulation of hematopoietic stem cells paves the way for their use in the management of autologous HSC transplantation (AHSCT). We aimed to evaluate the predictive value of circulatory microRNAs in extracellular vesicles (EVs) and plasma in platelet and neutrophil engraftment. Circulatory miR-125b, mir-126, miR-150, and miR-155 expression was assessed in isolated EVs and plasma in samples collected from AHSCT candidates. Multivariate analysis, COX models, and ROC assessment were performed to evaluate the predictive values of these microRNAs in platelet and neutrophil engraftment. miR-155 expression following conditioning with other clinical factors such as chemotherapy courses after diagnosis was the most significant predictors of platelet/neutrophil engraftment. A CD34+ cell count ≥ 3.5 × 106/kg combined with miR-155 could be used as an engraftment predictor; however, in cases where the CD34+ cell count was < 3.5 × 106/kg, this parameter lost its predictive value for engraftment and could be replaced by miR-155. The correlation between miR-155 and platelet/neutrophil engraftment even with lower numbers of CD34+ cells suggests the importance of this microRNA in the prediction of AHSCT outcome. Moreover, miR-155 could be utilized in therapeutic approaches to provide a better outcome for patients undergoing AHSCT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hübel K, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, et al. Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transpl. 2019;54(1):123–9.CrossRef Hübel K, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, et al. Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transpl. 2019;54(1):123–9.CrossRef
2.
Zurück zum Zitat Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases–a guide for the generalist. Clin Med. 2018;18(4):329.CrossRef Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases–a guide for the generalist. Clin Med. 2018;18(4):329.CrossRef
3.
Zurück zum Zitat Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Tr. 2014;20(3):295–308.CrossRef Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Tr. 2014;20(3):295–308.CrossRef
4.
Zurück zum Zitat Kim JS. Hematopoietic stem cell mobilization: current status and future perspective. Blood Res. 2017;52(2):79–81.CrossRef Kim JS. Hematopoietic stem cell mobilization: current status and future perspective. Blood Res. 2017;52(2):79–81.CrossRef
5.
Zurück zum Zitat Calvi LM, Link DC. The hematopoietic stem cell niche in homeostasis and disease. Blood. 2015;126(22):2443–51.CrossRef Calvi LM, Link DC. The hematopoietic stem cell niche in homeostasis and disease. Blood. 2015;126(22):2443–51.CrossRef
6.
Zurück zum Zitat Roden C, Lu J. MicroRNAs in control of stem cells in normal and malignant hematopoiesis. Curr Stem Cell Rep. 2016;2(3):183–96.CrossRef Roden C, Lu J. MicroRNAs in control of stem cells in normal and malignant hematopoiesis. Curr Stem Cell Rep. 2016;2(3):183–96.CrossRef
7.
8.
Zurück zum Zitat Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018;9(1):320.CrossRef Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018;9(1):320.CrossRef
9.
Zurück zum Zitat Wang S-Y, Hong Q, Zhang C-Y, Yang Y-J, Cai G-Y, Chen X-M. miRNAs in stem cell-derived extracellular vesicles for acute kidney injury treatment: comprehensive review of preclinical studies. Stem Cell Res Ther. 2019;10(1):1–7.CrossRef Wang S-Y, Hong Q, Zhang C-Y, Yang Y-J, Cai G-Y, Chen X-M. miRNAs in stem cell-derived extracellular vesicles for acute kidney injury treatment: comprehensive review of preclinical studies. Stem Cell Res Ther. 2019;10(1):1–7.CrossRef
10.
Zurück zum Zitat Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909–22.CrossRef Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909–22.CrossRef
11.
Zurück zum Zitat Song G-Y, Jung S-H, Ahn S-Y, Jung S-Y, Yang D-H, Ahn J-S, et al. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. BMC Cancer. 2019;19(1):59.CrossRef Song G-Y, Jung S-H, Ahn S-Y, Jung S-Y, Yang D-H, Ahn J-S, et al. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. BMC Cancer. 2019;19(1):59.CrossRef
12.
Zurück zum Zitat Wang S, Min J, Yu Y, Yin L, Wang Q, Shen H, et al. Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm. J Thorac Dis. 2019;11(10):4337.CrossRef Wang S, Min J, Yu Y, Yin L, Wang Q, Shen H, et al. Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm. J Thorac Dis. 2019;11(10):4337.CrossRef
13.
Zurück zum Zitat Zhang L, Li H, Yuan M, Li D, Sun C, Wang G. Serum exosomal microRNAs as potential circulating biomarkers for endometriosis. Dis Markers. 2020;2020:2456340.PubMedPubMedCentral Zhang L, Li H, Yuan M, Li D, Sun C, Wang G. Serum exosomal microRNAs as potential circulating biomarkers for endometriosis. Dis Markers. 2020;2020:2456340.PubMedPubMedCentral
14.
Zurück zum Zitat Tian F, Shen Y, Chen Z, Li R, Ge Q. No significant difference between plasma miRNAs and plasma-derived exosomal miRNAs from healthy people. Biomed Res Int. 2017;2017:1304816.PubMedPubMedCentral Tian F, Shen Y, Chen Z, Li R, Ge Q. No significant difference between plasma miRNAs and plasma-derived exosomal miRNAs from healthy people. Biomed Res Int. 2017;2017:1304816.PubMedPubMedCentral
16.
Zurück zum Zitat Salvucci O, Jiang K, Gasperini P, Maric D, Zhu J, Sakakibara S, et al. MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1. Haematologica. 2012;97(6):818–26.CrossRef Salvucci O, Jiang K, Gasperini P, Maric D, Zhu J, Sakakibara S, et al. MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1. Haematologica. 2012;97(6):818–26.CrossRef
17.
Zurück zum Zitat Itkin T, Kumari A, Schneider E, Gur-Cohen S, Ludwig C, Brooks R, et al. MicroRNA-155 promotes G-CSF-induced mobilization of murine hematopoietic stem and progenitor cells via propagation of CXCL12 signaling. Leukemia. 2017;31(5):1247–50.CrossRef Itkin T, Kumari A, Schneider E, Gur-Cohen S, Ludwig C, Brooks R, et al. MicroRNA-155 promotes G-CSF-induced mobilization of murine hematopoietic stem and progenitor cells via propagation of CXCL12 signaling. Leukemia. 2017;31(5):1247–50.CrossRef
18.
Zurück zum Zitat Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS ONE. 2011;6(10):e23114.CrossRef Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS ONE. 2011;6(10):e23114.CrossRef
19.
Zurück zum Zitat Ooi AL, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA. 2010;107(50):21505–10.CrossRef Ooi AL, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA. 2010;107(50):21505–10.CrossRef
22.
Zurück zum Zitat Yamaguchi J, Chinen Y, Takimoto-Shimomura T, Nagata H, Muramatsu A, Kuriyama K, et al. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60(14):3434–41.CrossRef Yamaguchi J, Chinen Y, Takimoto-Shimomura T, Nagata H, Muramatsu A, Kuriyama K, et al. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60(14):3434–41.CrossRef
23.
Zurück zum Zitat Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–9.CrossRef Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–9.CrossRef
24.
Zurück zum Zitat Takizawa H, Kubo-Akashi C, Nobuhisa I, Kwon S-M, Iseki M, Taga T, et al. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein. Lnk Blood. 2006;107(7):2968–75.CrossRef Takizawa H, Kubo-Akashi C, Nobuhisa I, Kwon S-M, Iseki M, Taga T, et al. Enhanced engraftment of hematopoietic stem/progenitor cells by the transient inhibition of an adaptor protein. Lnk Blood. 2006;107(7):2968–75.CrossRef
25.
Zurück zum Zitat Zhang Y, Roos M, Himburg H, Termini CM, Quarmyne M, Li M, et al. PTPσ inhibitors promote hematopoietic stem cell regeneration. Nat Commun. 2019;10(1):1–15.CrossRef Zhang Y, Roos M, Himburg H, Termini CM, Quarmyne M, Li M, et al. PTPσ inhibitors promote hematopoietic stem cell regeneration. Nat Commun. 2019;10(1):1–15.CrossRef
26.
Zurück zum Zitat Noach EJ, Ausema A, van Os R, Akkerman I, Koopal S, Weersing E, et al. Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. Exp Hematol. 2003;31(6):528–34.CrossRef Noach EJ, Ausema A, van Os R, Akkerman I, Koopal S, Weersing E, et al. Chemotherapy prior to autologous bone marrow transplantation impairs long-term engraftment in mice. Exp Hematol. 2003;31(6):528–34.CrossRef
27.
Zurück zum Zitat Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med. 2013;19(6):695.CrossRef Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med. 2013;19(6):695.CrossRef
29.
Zurück zum Zitat Lee K, Jung S, Kim S, Jang J, Kim K, Kim W, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang. 2014;107(4):407–15.CrossRef Lee K, Jung S, Kim S, Jang J, Kim K, Kim W, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang. 2014;107(4):407–15.CrossRef
30.
Zurück zum Zitat Weaver C, Birch R, Greco F, Schwartzberg L, McAneny B, Moore M, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;100(2):338–47.CrossRef Weaver C, Birch R, Greco F, Schwartzberg L, McAneny B, Moore M, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol. 1998;100(2):338–47.CrossRef
32.
Zurück zum Zitat Xu Y, Yao Y, Yao W, Jin S, Yan L, Shang J, et al. Application of the conditioning regimen with busulfan and cyclophosphamide in autologous hematopoietic stem cell transplantation in multiple myeloma. Blood. 2017;130(Supplement 1):5517. Xu Y, Yao Y, Yao W, Jin S, Yan L, Shang J, et al. Application of the conditioning regimen with busulfan and cyclophosphamide in autologous hematopoietic stem cell transplantation in multiple myeloma. Blood. 2017;130(Supplement 1):5517.
33.
Zurück zum Zitat Reshef R, Porter D. Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transpl. 2015;50(6):759–69.CrossRef Reshef R, Porter D. Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transpl. 2015;50(6):759–69.CrossRef
Metadaten
Titel
Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis
verfasst von
Mohammad Rafiee
Mehdi Allahbakhshian Farsani
Vahid Amiri
Abbas Hajifathali
Ahmad Gharehbaghian
Mohammad Hossein Mohammadi
Publikationsdatum
24.04.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 2/2021
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03154-2

Weitere Artikel der Ausgabe 2/2021

International Journal of Hematology 2/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.